HC Wainwright Issues Pessimistic Forecast for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – HC Wainwright dropped their FY2027 earnings estimates for shares of Unicycive Therapeutics in a report released on Wednesday, May 13th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $1.58 for the year, down from their prior estimate of $1.60. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is $0.02 per share.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.08).

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, March 27th. Westpark Capital started coverage on shares of Unicycive Therapeutics in a research note on Thursday, February 19th. They set a “buy” rating for the company. Guggenheim reissued a “buy” rating and set a $37.00 target price (down from $40.00) on shares of Unicycive Therapeutics in a research note on Wednesday. Benchmark decreased their target price on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating for the company in a research note on Monday, April 6th. Finally, Wall Street Zen lowered shares of Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Unicycive Therapeutics Stock Performance

Unicycive Therapeutics stock opened at $8.51 on Thursday. The company has a 50 day moving average price of $7.07 and a 200 day moving average price of $6.36. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $11.00. The firm has a market capitalization of $227.22 million, a price-to-earnings ratio of -3.85 and a beta of 1.78.

Institutional Investors Weigh In On Unicycive Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP acquired a new stake in shares of Unicycive Therapeutics during the 1st quarter valued at $940,000. Quadrature Capital Ltd bought a new position in shares of Unicycive Therapeutics during the 4th quarter valued at $226,000. Millennium Management LLC bought a new position in shares of Unicycive Therapeutics during the 4th quarter valued at $5,856,000. Cantor Fitzgerald L. P. bought a new position in shares of Unicycive Therapeutics during the 4th quarter valued at $1,154,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Unicycive Therapeutics during the 4th quarter valued at $451,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.